Dynavax Technologies Corporation (DVAX) - שולי רווח נקי ממכירות

Dynavax Corp (DVAX) - לוגו תאגידי

Dynavax Technologies (DVAX) revenues are based on the sales of the Heplisav-B hepatitis B vaccine. The net profit margin reflects profit dynamics, where the -13.10 mark records this indicator. Funds from the core product are invested in oncology research to diversify risks. A stable staff of leading scientists and the absence of a talent shortage in R&D ensure the long-term growth potential of the business.

DVAX: שולי רווח נקי Dynavax Pharma 04.07.2022 - 21.02.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Dynavax Pharma (DVAX)

- שווי שוק ותחזית יעד של אנליסטים:
אנליטיקה מסכמת של החברה:Dynavax Pharma, DVAX
מוצרים מוגמרים של Dynavax Corp

Net margin determines the portion of revenue remaining as profit after deducting all operating and financial expenses, serving as an indicator of asset monetization efficiency. By analyzing the net profitability of sales, an investor can see how the costs of third-party CMO manufacturing outsourcing at Dynavax Technologies (DVAX) impact the final financial result and the overall stability of the company's business model.